| III-41 Jin Jin Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Thursday 09:50-11:20 |
| III-41 Jin Jin Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Thursday 09:50-11:20 |